Identification

Name
Saprisartan
Accession Number
DB01347
Type
Small Molecule
Groups
Experimental
Description

Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism [1].

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Saprisartan potassiumT28707PG7T146613-90-3IASZJGRIPLTJMA-UHFFFAOYSA-N
Categories
UNII
HS64NG1G69
CAS number
146623-69-0
Weight
Average: 611.431
Monoisotopic: 610.049723164
Chemical Formula
C25H22BrF3N4O4S
InChI Key
DUEWVPTZCSAMNB-UHFFFAOYSA-N
InChI
InChI=1S/C25H22BrF3N4O4S/c1-2-19-31-21(14-8-9-14)22(24(30)34)33(19)12-13-7-10-18-16(11-13)20(26)23(37-18)15-5-3-4-6-17(15)32-38(35,36)25(27,28)29/h3-7,10-11,14,32H,2,8-9,12H2,1H3,(H2,30,34)
IUPAC Name
1-{[3-bromo-2-(2-trifluoromethanesulfonamidophenyl)-1-benzofuran-5-yl]methyl}-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide
SMILES
CCC1=NC(C2CC2)=C(N1CC1=CC2=C(OC(=C2Br)C2=CC=CC=C2NS(=O)(=O)C(F)(F)F)C=C1)C(N)=O

Pharmacology

Indication

Saprisartan is used in the treatment of hypertension and heart failure.

Structured Indications
Not Available
Pharmacodynamics

By inhibiting the angiotensin II receptor, this drug leades to a decrease in sodium reabsorption and a decrease in vasoconstriction. This has the combined effect of decreasing blood pressure.

Mechanism of action

Saprisartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Saprisartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Saprisartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors.

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Saprisartan.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Saprisartan.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Acemetacin.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Alclofenac.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Saprisartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Saprisartan.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Alminoprofen.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Saprisartan.Approved, Withdrawn
AmbrisentanSaprisartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineSaprisartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideSaprisartan may increase the hyperkalemic activities of Amiloride.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Saprisartan.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Saprisartan.Approved, Illicit
AndrographolideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Saprisartan is combined with Apocynin.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Saprisartan is combined with Apremilast.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Saprisartan.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Saprisartan.Approved
AvanafilAvanafil may increase the antihypertensive activities of Saprisartan.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azelastine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Balsalazide.Approved, Investigational
BemiparinBemiparin may increase the hyperkalemic activities of Saprisartan.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Saprisartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Saprisartan.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benzydamine.Approved
BepridilBepridil may increase the hypotensive activities of Saprisartan.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Saprisartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Saprisartan.Approved
BevoniumThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Saprisartan.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Saprisartan.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Saprisartan.Approved
BosentanBosentan may increase the hypotensive activities of Saprisartan.Approved, Investigational
BQ-123Saprisartan may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Saprisartan.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Saprisartan.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Saprisartan.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bumadizone.Experimental
BupranololSaprisartan may increase the hypotensive activities of Bupranolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Saprisartan.Experimental
CafedrineSaprisartan may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Saprisartan.Approved
CandesartanSaprisartan may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Saprisartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Captopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Saprisartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Saprisartan.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Saprisartan.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Celecoxib.Approved, Investigational
CeliprololSaprisartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Saprisartan.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Saprisartan.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Saprisartan.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Choline magnesium trisalicylate.Approved
CicletanineSaprisartan may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Cilazapril.Approved
CiprofloxacinSaprisartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClonidineClonidine may increase the hypotensive activities of Saprisartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Clonixin.Approved
CloranololSaprisartan may increase the hypotensive activities of Cloranolol.Experimental
CryptenamineCryptenamine may increase the hypotensive activities of Saprisartan.Approved
CurcuminThe risk or severity of adverse effects can be increased when Saprisartan is combined with Curcumin.Investigational
CyclopenthiazideSaprisartan may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineSaprisartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Saprisartan.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Saprisartan is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Saprisartan.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Saprisartan.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Saprisartan.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Delapril.Experimental
DeserpidineSaprisartan may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Saprisartan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Diclofenac.Approved, Vet Approved
diethylnorspermineSaprisartan may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Saprisartan is combined with Diflunisal.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Saprisartan.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Saprisartan.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Saprisartan.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Saprisartan.Approved
DrospirenoneSaprisartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Saprisartan is combined with E-6201.Investigational
EfonidipineSaprisartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Saprisartan is combined with Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Saprisartan.Experimental
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Saprisartan.Approved
EpanololSaprisartan may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Saprisartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Saprisartan.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Saprisartan.Approved
EprosartanEprosartan may increase the hypotensive activities of Saprisartan.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ethenzamide.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Saprisartan is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Saprisartan.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Saprisartan.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Feprazone.Experimental
Ferulic acidSaprisartan may increase the hypotensive activities of Ferulic acid.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Flurbiprofen.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Saprisartan.Approved, Investigational, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Saprisartan is combined with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Saprisartan.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Saprisartan.Approved
GuanazodineSaprisartan may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Saprisartan.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Saprisartan.Approved, Investigational
GuanoclorSaprisartan may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzSaprisartan may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanSaprisartan may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Saprisartan.Experimental
HeparinHeparin may increase the hyperkalemic activities of Saprisartan.Approved, Investigational
HexamethoniumSaprisartan may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Saprisartan.Experimental
HydralazineHydralazine may increase the hypotensive activities of Saprisartan.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Saprisartan.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Saprisartan.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Saprisartan is combined with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Saprisartan.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Imidazole salicylate.Experimental
IndapamideIndapamide may increase the hypotensive activities of Saprisartan.Approved
IndenololSaprisartan may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Saprisartan.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Saprisartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Saprisartan.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Saprisartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Saprisartan.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Saprisartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Saprisartan.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Saprisartan.Approved
LacidipineSaprisartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Saprisartan.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Saprisartan.Approved, Investigational
LinsidomineSaprisartan may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Saprisartan.Approved
LofexidineSaprisartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lornoxicam.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Saprisartan.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lumiracoxib.Approved, Investigational
MacitentanSaprisartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Magnesium salicylate.Approved
ManidipineSaprisartan may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Saprisartan is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Saprisartan.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Saprisartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Saprisartan is combined with Metamizole.Investigational, Withdrawn
MethoserpidineSaprisartan may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Saprisartan.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Saprisartan.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Saprisartan.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Saprisartan.Approved
MetolazoneMetolazone may increase the hypotensive activities of Saprisartan.Approved
MetoprololMetoprolol may increase the hypotensive activities of Saprisartan.Approved, Investigational
MetyrosineSaprisartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilSaprisartan may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Saprisartan.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Saprisartan.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Saprisartan.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Saprisartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Saprisartan.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Saprisartan.Approved, Investigational
MuzolimineSaprisartan may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Saprisartan.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Saprisartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Naftifine.Approved
NaftopidilSaprisartan may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Naproxen.Approved, Vet Approved
NebivololSaprisartan may increase the hypotensive activities of Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Saprisartan.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Saprisartan.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Saprisartan.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Niflumic Acid.Approved
NiguldipineSaprisartan may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineSaprisartan may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Saprisartan.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Saprisartan.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Saprisartan.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Saprisartan.Approved
ObinutuzumabSaprisartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Saprisartan.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Saprisartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Saprisartan is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Oxaprozin.Approved
OxprenololSaprisartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Oxyphenbutazone.Approved, Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Saprisartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Saprisartan.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Parthenolide.Investigational
PenbutololSaprisartan may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Saprisartan.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Saprisartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Saprisartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Saprisartan.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Saprisartan.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Saprisartan.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Saprisartan.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Saprisartan.Withdrawn
PindololPindolol may increase the hypotensive activities of Saprisartan.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Saprisartan.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Saprisartan.Withdrawn
Platelet Activating FactorSaprisartan may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Saprisartan.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pranoprofen.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Saprisartan.Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Saprisartan.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Saprisartan is combined with Propacetamol.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Saprisartan.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Proquazone.Experimental
PTC299The risk or severity of adverse effects can be increased when Saprisartan is combined with PTC299.Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Saprisartan.Approved
RamiprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Saprisartan.Approved
RemikirenRemikiren may increase the hypotensive activities of Saprisartan.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Saprisartan.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Saprisartan is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Saprisartan.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Saprisartan.Investigational
RiociguatSaprisartan may increase the hypotensive activities of Riociguat.Approved
RituximabSaprisartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Rofecoxib.Investigational, Withdrawn
SafrazineSafrazine may increase the hypotensive activities of Saprisartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salsalate.Approved
SelegilineSelegiline may increase the hypotensive activities of Saprisartan.Approved, Investigational, Vet Approved
SelexipagSaprisartan may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Saprisartan is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Saprisartan is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Saprisartan is combined with Serrapeptase.Investigational
SildenafilSildenafil may increase the antihypertensive activities of Saprisartan.Approved, Investigational
SitaxentanSaprisartan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphateSaprisartan may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Spirapril.Approved
SpironolactoneSaprisartan may increase the hyperkalemic activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Saprisartan is combined with SRT501.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Saprisartan.Approved, Investigational
TalinololSaprisartan may increase the hypotensive activities of Talinolol.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tarenflurbil.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Saprisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Teriflunomide.Approved
TerlipressinSaprisartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineSaprisartan may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineSaprisartan may increase the hypotensive activities of Theodrenaline.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tiaprofenic acid.Approved
TiboloneSaprisartan may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenSaprisartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Saprisartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Saprisartan.Approved
TolazolineTolazoline may increase the hypotensive activities of Saprisartan.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tolmetin.Approved
TolonidineSaprisartan may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Saprisartan.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Saprisartan.Approved
TorasemideTorasemide may increase the hypotensive activities of Saprisartan.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Saprisartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Saprisartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Saprisartan.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Saprisartan.Approved, Investigational
TriamtereneSaprisartan may increase the hyperkalemic activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Saprisartan.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Saprisartan.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Saprisartan.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Saprisartan.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Triptolide.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Saprisartan.Approved, Investigational
UnoprostoneSaprisartan may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Saprisartan.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Valdecoxib.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Saprisartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Saprisartan.Approved
VincamineSaprisartan may increase the hypotensive activities of Vincamine.Experimental
VinpocetineSaprisartan may increase the hypotensive activities of Vinpocetine.Investigational
XipamideSaprisartan may increase the hypotensive activities of Xipamide.Experimental
XylometazolineSaprisartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Saprisartan.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
  1. Timmermans PB: Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. [PubMed:10579749]
External Links
Human Metabolome Database
HMDB15437
PubChem Compound
60921
PubChem Substance
46508176
ChemSpider
54892
ChEMBL
CHEMBL305544
Therapeutic Targets Database
DAP001257
PharmGKB
PA164746338

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0151 mg/mLALOGPS
logP5.89ALOGPS
logP3.35ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)2.27ChemAxon
pKa (Strongest Basic)5.18ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area120.22 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity137.15 m3·mol-1ChemAxon
Polarizability54.2 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.647
Caco-2 permeable-0.6148
P-glycoprotein substrateSubstrate0.5611
P-glycoprotein inhibitor INon-inhibitor0.6454
P-glycoprotein inhibitor IINon-inhibitor0.5279
Renal organic cation transporterNon-inhibitor0.8625
CYP450 2C9 substrateNon-substrate0.653
CYP450 2D6 substrateNon-substrate0.7866
CYP450 3A4 substrateSubstrate0.5105
CYP450 1A2 substrateNon-inhibitor0.6561
CYP450 2C9 inhibitorInhibitor0.6267
CYP450 2D6 inhibitorNon-inhibitor0.7996
CYP450 2C19 inhibitorInhibitor0.5274
CYP450 3A4 inhibitorNon-inhibitor0.5167
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8837
Ames testNon AMES toxic0.5853
CarcinogenicityNon-carcinogens0.6378
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5781 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9673
hERG inhibition (predictor II)Inhibitor0.6568
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 2-arylbenzofuran flavonoids. These are phenylpropanoids containing the 2-phenylbenzofuran moiety.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
2-arylbenzofuran flavonoids
Sub Class
Not Available
Direct Parent
2-arylbenzofuran flavonoids
Alternative Parents
2-phenylbenzofurans / Sulfanilides / 1,2,4,5-tetrasubstituted imidazoles / 2-heteroaryl carboxamides / Carbonylimidazoles / Organosulfonamides / Aryl bromides / Organic sulfonamides / N-substituted imidazoles / Aminosulfonyl compounds
show 14 more
Substituents
2-arylbenzofuran flavonoid / 2-phenylbenzofuran / Phenylbenzofuran / Sulfanilide / 1,2,4,5-tetrasubstituted imidazole / Benzofuran / 2-heteroaryl carboxamide / Imidazole-4-carbonyl group / Aryl bromide / Aryl halide
show 35 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Timmermans PB: Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. [PubMed:10579749]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 30, 2007 12:15 / Updated on November 09, 2017 02:59